Google Alert - "LSD1 inhibitor" OR "sickle cell disease" · Scour

Antiviral nasal spray secures multimillion‑dollar boost - Newsroom

Can transcranial Doppler improve risk stratification in pediatric moyamoya?

To lead in global innovation, Canada must prioritize basic science

Ending the Status Quo: Why Black Patients Deserve Better Sickle Cell Care

Vertex earnings get muted investor response

Vertex's quiet Q1 is calm before potentially 'iconic' renal evolution

Disc Medicine Reports First Quarter 2026 Financial Results

How scientists made the discoveries behind a game-changing gene therapy for sickle cell disease

Harckham and Levenberg want improved care for children with severe illness

Asembia ASX26: How Payers are Embracing Value-Based Care Models for Cell & Gene Therapies

Sickle cell treatment study finds NYC ahead of state

Vertex tops profit estimates as sales of new cystic fibrosis drug surge

CRISPR Gene Therapy Shows Promise in Sickle Cell Disease

1X expands to Hayward, Bay Area housing affordability worst in U.S. - San Francisco Business Times

NJ Legislation | 2026-2027 | Regular Session

Vertex Pharmaceuticals Incorporated (VRTX) Q1 2026 Earnings Call Transcript

Vertex tops profit estimates as sales of new cystic fibrosis drug surge

Vertex Pharmaceuticals Q1 2026 Earnings Call: Complete Transcript

Vertex Pharmaceuticals (NASDAQ:VRTX) Beats Q1 Estimates as New Drug Launches Drive ...

Vertex Pharmaceuticals Posts Higher 1Q Profit

Log in to enable infinite scrolling